We are live on !
Find out more
Johnson & Johnson Portfolio holdings
AUM
$762M
Turnover
0%
1-Year Est. Return
69.66%
This Fund
S&P 500
This Quarter Est. Return
+104.06%
1 Year Est. Return
+69.66%
3 Year Est. Return
+338.66%
5 Year Est. Return
+421.86%
10 Year Est. Return
–
AUM
$504M
AUM Growth
+$170M
(+51%)
Cap. Flow
-$12.6M
Cap. Flow % of AUM
Cap. Flow %
-2.49%
Top 10 Holdings %
Top 10 Hldgs %
97.16%
Holding
20
New
–
Increased
1
Reduced
2
Closed
–
Avg Time Held
3.1
years
Top 10 Avg Time Held
2.4
years
Top 20 Avg Time Held
2.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lyell Immunopharma
LYEL
|
+$157K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rapport Therapeutics
RAPP
|
+$12.7M |
| 2 |
Vor Biopharma
VOR
|
+$40 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Protagonist Therapeutics
PTGX
$9.2B
| $163M | 32.29% |
2,449,183
| – | – |
2021 Q3
16 quarters
|
|
2
Nanobiotix
NBTX
$1.73B
| $106M | 21.08% |
5,623,816
| – | – |
2023 Q3
8 quarters
|
|
3
MeiraGTx Holdings
MGTX
$936M
| $54.7M | 10.85% |
6,641,064
| – | – |
2021 Q3
16 quarters
|
|
|
4
Rapport Therapeutics
RAPP
$1.08B
| $53M | 10.52% |
1,784,517
-713,534
| -29% | -$12.7M |
2024 Q2
5 quarters
|
|
5
CVRx
CVRX
$37.3M
| $33.1M | 6.57% |
4,103,430
| – | – |
2021 Q3
16 quarters
|
|
6
Legend Biotech
LEGN
$4.38B
| $26.6M | 5.27% |
814,586
| – | – |
2021 Q3
16 quarters
|
|
7
Contineum Therapeutics
CTNM
$344M
| $23.3M | 4.61% |
1,979,173
| – | – |
2024 Q2
5 quarters
|
|
8
Procept Biorobotics
PRCT
$1.16B
| $12.8M | 2.54% |
357,939
| – | – |
2021 Q3
16 quarters
|
|
9
Xencor
XNCR
$2.23B
| $8.77M | 1.74% |
748,062
| – | – |
2021 Q4
15 quarters
|
|
10
Arrowhead Research
ARWR
$8.5B
| $8.54M | 1.69% |
247,598
| – | – |
2021 Q3
16 quarters
|
|
11
Fate Therapeutics
FATE
$260M
| $4.26M | 0.84% |
3,379,064
| – | – |
2021 Q3
16 quarters
|
|
12
Neumora Therapeutics
NMRA
$73.9M
| $3.37M | 0.67% |
1,849,445
| – | – |
2023 Q3
8 quarters
|
|
|
13
Vor Biopharma
VOR
$1.22B
| $2.62M | 0.52% |
53,732
-1
| -0% | -$40 |
2021 Q3
16 quarters
|
|
14
Rallybio
RLYB
$86.1M
| $1.81M | 0.36% |
454,545
| – | – |
2024 Q2
5 quarters
|
|
|
15
Lyell Immunopharma
LYEL
$268M
| $891K | 0.18% |
54,887
+13,722
| +33% | +$157K |
2024 Q4
3 quarters
|
|
16
Nano X Imaging
NNOX
$25.3M
| $588K | 0.12% |
158,852
| – | – |
2021 Q4
15 quarters
|
|
17
Standard BioTools
LAB
$244M
| $406K | 0.08% |
311,967
| – | – |
2024 Q1
6 quarters
|
|
18
Adicet Bio
ACET
$35.7M
| $295K | 0.06% |
22,780
| – | – |
2021 Q3
16 quarters
|
|
|
HLSQ
19
Tessera Defense and Homeland Security Inc.
HLSQ
$3.66M
| $50.9K | 0.01% |
510
| – | – |
2021 Q3
16 quarters
|
|
20
Senseonics Holdings Inc
SENS
$494M
| $23.8K | ﹤0.01% |
2,731
| – | – |
2021 Q3
16 quarters
|
|
Similar funds
Johnson & Johnson's Q3 2025 Portfolio in Review
As of Q3 2025, Johnson & Johnson held 20 positions worth $504M, up 51% from $334M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Trading was light in Q3 2025: portfolio turnover was 0%. Johnson & Johnson opened no new positions and made no exits, leaving the 20-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Johnson & Johnson added most to Lyell Immunopharma in Q3 2025, an estimated $157K increase.
- Johnson & Johnson's biggest Q3 2025 reduction was Rapport Therapeutics, cutting an estimated $12.7M.
- Johnson & Johnson's ten largest holdings make up 97% of its $504M portfolio in Q3 2025.
- Johnson & Johnson opened 0 new positions and closed 0 in Q3 2025.
- Johnson & Johnson's portfolio value rose 51% quarter-over-quarter to $504M.
Based on Johnson & Johnson's 13F filing for Q3 2025, filed 13 Nov 2025.